Trophic factors in aging. Should older people receive hormonal replacement therapy?
The aging process is associated with significant declines in the levels of many hormones and trophic factors including estrogen, testosterone, growth hormone (somatropin, somatotropin) and insulin-like growth factor-1 (IGF-1, somatomedin-1, somatomedin-C). Since the classic age-related changes resemble the signs and symptoms of endocrine deficiency, it has been hypothesised that some of the negative effects of aging are due to these hormonal deficits. Consequently, the potential role of hormonal replacement in reversing the deleterious effects of aging deserves investigation. In old hypogonadal men, preliminary studies have shown that testosterone replacement not only improves libido but also significantly increases musculoskeletal mass and strength. However, adverse effects have included increases in haematocrit and prostate specific antigen. Similarly, short term studies with growth hormone replacement have shown substantial bodyweight gain, particularly in severely malnourished older adults, but longer studies have been limited by adverse effects such as gynaecomastia and carpal tunnel syndrome in a few people. Thus, though both testosterone and growth hormone may have potential roles for frailty syndromes in the elderly, long term clinical trials are needed to confirm these positive effects and assess their safety. On the other hand, the multiple beneficial effects of estrogen replacement in older women such as relieving acute menopausal symptoms and preventing postmenopausal osteoporosis are well recognised. Observational studies also suggest that estrogen may decrease cardiovascular disease. However, the optimum duration of treatment and the best way to administer this hormone are still unknown. Also, estrogen may be less effective in senile osteoporosis which primarily results from age-related bone loss. Traditionally, age-related bone loss has been attributed to impaired vitamin D activation and decreased calcium absorption. Thus, it was thought that such bone losses may be ameliorated by calcium supplementation. However, recent studies suggest that alterations in local factors affecting bone cell function may also be important in the pathogenesis of osteoporosis. An increase in potent bone resorbing factors, such as the cytokines interleukin-1 and interleukin-6, has been recently demonstrated in elderly patients with osteoporosis. In these patients, it has been suggested that there may also be a decrease in bone growth factors such as IGF-1 and transforming growth factor-beta. Accordingly, studies are underway to determine whether these factors may be useful in the prevention of osteoporosis. Other growth factors recently identified which may be important in aging include epidermal growth factor, nerve growth factor and fibroblast growth factor.(ABSTRACT TRUNCATED AT 400 WORDS)
Villareal
D T
DT
Geriatric Research Education and Clinical Center, St Louis Veterans Administration Medical Center, Missouri.
Morley
J E
JE
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000172:deficiency / Q000378:metabolism; D000368:Aged; D000375:Aging / Q000378:metabolism*; D000818:Animals; D002118:Calcium / Q000378:metabolism; D004702:Endocrine Glands / Q000378:metabolism*; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000172:deficiency / Q000378:metabolism; D005260:Female; D006133:Growth Substances / Q000172:deficiency / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D013739:Testosterone / Q000008:administration & dosage* / Q000172:deficiency / Q000378:metabolism; D013963:Thyroid Hormones / Q000008:administration & dosage / Q000172:deficiency / Q000378:metabolism
D000305:Adrenal Cortex Hormones; D004967:Estrogens; D006133:Growth Substances; D013963:Thyroid Hormones; D013739:Testosterone; D002118:Calcium